| A | B | C | |
|---|---|---|---|
| 1 | Main | ||
| 2 | Brand Name | Invokana | |
| 3 | Generic Name | canagliflozin | |
| 4 | Indication | Type 2 Diabetes | |
| 5 | Economics | Mitsubishi Tanabe | |
| 6 | Mechanism | SGLT2 | |
| 7 | Clinical Trials | ||
| 8 | Phase III vs Januvia n=475 | ||
| 9 | |||
| 10 | Phase III "CANVAS" n=4500 CV study |
| A | B | C | |
|---|---|---|---|
| 1 | Main | ||
| 2 | Brand Name | Invokana | |
| 3 | Generic Name | canagliflozin | |
| 4 | Indication | Type 2 Diabetes | |
| 5 | Economics | Mitsubishi Tanabe | |
| 6 | Mechanism | SGLT2 | |
| 7 | Clinical Trials | ||
| 8 | Phase III vs Januvia n=475 | ||
| 9 | |||
| 10 | Phase III "CANVAS" n=4500 CV study |
Martin Shkreli